Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer

Authors

Sima Kadkhodayan1, Fateme Homaee Shandiz2,*, Mehdi Seilanian Toussi2, Monavar Afzal Aghaee3, Farnoosh Farshidi4, Parvane Dehghan5
1Women’s Health Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
2Solid Tumor Treatment Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
3Dept. of Epidemiology, Mashhad University of Medical Sciences, Mashhad, Iran
4Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
5Dept. of Radiation Oncology, Mashhad University of Medical Sciences, Mashhad, Iran
*Corresponding Author: Corresponding author: Fateme Homaee Shandiz, Solid Tumor Treatment Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran, Tel: +98-5118012477, E-mail: Email: [email protected]

International Journal of Cancer Management:Vol. 6, issue 4; e80468
Published online:Dec 30, 2013
Article type:Research Article
Received:Jun 30, 2013
Accepted:Sep 03, 2013
How to Cite:Kadkhodayan S, Homaee Shandiz F, Seilanian Toussi M, Afzal Aghaee M, Farshidi F, et al. Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer. Int J Cancer Manag. 2013;6(4):e80468. doi:

Abstract

Background: Concurrent chemoradiotherapy (EBRT + cisplatin) plus intracavitary brachytherapy is the standard of care in patients with advanced cervical cancer. However, a number of patients could not undergone brachytherapy due to massive residual tumor or anatomical distortion. In this study, we have evaluated the treatment outcome in patients with locally advanced cervical cancer, undergone conventional EBRT plus cisplatin based chemotherapy.

Methods: In this study, we have selected patients with locally advanced cervical carcinoma (stage: IIB to IIIB) undergone external beam radiotherapy and chemotherapy without brachytherapy at our institute between October of 2007 and October of 2009. The patients have received 50 Gy within 5 weeks to whole pelvic that has followed by a localized boost dose on tumor to 70 Gy concurrently with cisplatin 35 mg/m2 weekly. The treatment has related toxicities, and survival (overall and disease free) have evaluated.

Results: 30 cases with a median age of 55 (range; 40 to 73) have been studied. According to FIGO classification, the clinical stages were as follows: stage: IIB 23, IIIA 4, and IIIB 3 cases. Three months after treatment, 19 patients (63.3%) have achieved complete response. With a median follow up time of 18 months (range; 10-33 months), 8/23 cases (34.7%) with stage IIB and 2/7 (28.5%) among stage IIIA-IIIB remained disease free at the end of follow up. Data have shown a 2- year overall survival rate of 58.7% ± 9% and 2- year disease free survival of 37.7% ± 9% . Most toxicities were grade I and II. 2 (6.6%) grade III diarrhea and 4 (13.3%) grade III neutropenia have recorded.

Conclusion: Although a considerable number of patients have achieved complete response using concurrent chemoradiotherapy without brachytherapy, the overall treatment outcomes especially for stage IIIA-IIIB were unsatisfactory. Using modern radiation therapy techniques with increased delivered boost dose could improve treatment results.

Fulltext

The Full text is available in PDF.

Copyright

© 2013, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

26
May
2026
Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer: A Comparative Retrospective Cohort Study

Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer: A Comparative Retrospective Cohort Study

Malihe Arab,
Fatemeh Dastyar,
Robab Anbiaiee,
Masoomeh Raoufi,
Maryam Hosseini,
Farah Farzaneh
,et al.

Arab M, Dastyar F, Anbiaiee R, Raoufi M, Hosseini M, et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer: A Comparative Retrospective Cohort Study. Int J Cancer Manag. 2026;19(1):e168905. doi: https://doi.org/10.5812/ijcm-168905

13
Nov
2024

Comparison of Neoadjuvant Chemotherapy Followed by Radical Surgery with Chemoradiation in Stage IB2 to IIB of Cervical Cancer

Maliheh Arab,
Fatemeh Hadi,
Masoomeh Raoufi,
Robab Anbiaee,
Somayyeh Noei Teymoordash,
Maryam Sadat Hosseini
,et al.

Arab M, Hadi F, Raoufi M, Anbiaee R, Teymoordash SN, et al. Comparison of Neoadjuvant Chemotherapy Followed by Radical Surgery with Chemoradiation in Stage IB2 to IIB of Cervical Cancer. Int J Cancer Manag. 2024;17(1):e148906. doi: https://doi.org/10.5812/ijcm-148906

24
Aug
2015

Evaluation of Survival and Treatment Toxicity With High-Dose-Rate Brachytherapy With Cobalt 60 in Carcinoma of Cervix

Afshin Rakhsha,
Amir Shahram Yousefi Kashi,
Seied Mohsen Hoseini

Rakhsha A, Yousefi Kashi AS, Hoseini SM. Evaluation of Survival and Treatment Toxicity With High-Dose-Rate Brachytherapy With Cobalt 60 in Carcinoma of Cervix. Int J Cancer Manag. 2015;8(4):e3573. doi: https://doi.org/10.17795/ijcp-3573

20
Jul
2022
High Dose Rate Brachytherapy Boost After Chemoradiation in Rectal Cancer Patients: A Retrospective Study

High Dose Rate Brachytherapy Boost After Chemoradiation in Rectal Cancer Patients: A Retrospective Study

Reyhaneh Bayani,
Nima Mousavi Darzikolaee,
Abdol Azim Sadighi Pashaki,
Pedram Fadavi,
Babak Hassanlouei,
Maryam Garousi

Bayani R, Mousavi Darzikolaee N, Sadighi Pashaki AA, Fadavi P, Hassanlouei B, et al. High Dose Rate Brachytherapy Boost After Chemoradiation in Rectal Cancer Patients: A Retrospective Study. Int J Cancer Manag. 2022;15(5):e121298. doi: https://doi.org/10.5812/ijcm-121298

17
Jun
2019

Evaluation of Survival Rate and Non-Fetal Outcomes in Patients with Esophageal Cancer Under Treatment with Neoadjuvant Chemoradiotherapy Plus Additional Platinium-Based Chemotherapy from 2010 to 2016

Hasan Ali Vahedian,
Mohsen Akhondi-Meybodi,
Fatemeh Mansouri,
Masoud Shabani

Vahedian HA, Akhondi-Meybodi M, Mansouri F, Shabani M. Evaluation of Survival Rate and Non-Fetal Outcomes in Patients with Esophageal Cancer Under Treatment with Neoadjuvant Chemoradiotherapy Plus Additional Platinium-Based Chemotherapy from 2010 to 2016. Int J Cancer Manag. 2019;12(6):e89003. doi: https://doi.org/10.5812/ijcm.89003

More by these authors

Sima KadkhodayanPubMedScholar
Fateme Homaee ShandizPubMedScholar
Mehdi Seilanian ToussiPubMedScholar
Monavar Afzal AghaeePubMedScholar
Farnoosh FarshidiPubMedScholar
Parvane DehghanPubMedScholar
Share
Cited by
Metrics